A pharmaceutical composition for preventing and treating scar hyperplasia, and its preparation method and application

Abstract

The present invention belongs to the technical field of pharmaceutical compositions, and relates to a pharmaceutical composition for preventing and treating scar hyperplasia, and a preparation method and application thereof. The pharmaceutical composition comprises the following ingredients: danshensu, tanshinone ⅡA, salvianolic acid A, ligustilide, ferulic acid, ligustrin, ligustrazine, ligustrin A, amygdalin, β-sitosterol acetate, kaempferol, baicalin, safflower glycosides, p-hydroxybenzaldehyde, β-sitosterol, gallic acid, epicatechin gallate, punica granatum, matrine, matrine A, α-boswellic acid, β-boswellic acid, atractylodes lactone III, dehydrocostus lactone, borneol, glycyrrhizic acid, liquiritin. Compared with the prior art, the present invention has clear ingredients and is better at preventing and treating scar hyperplasia.

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical compositions, and in particular relates to a pharmaceutical composition for preventing and treating scar hyperplasia and an application thereof. Background Art

[0002] Scars are local symptoms that affect both appearance and function due to physical, biological, chemical and other factors that damage the soft tissues of the human skin, causing severe damage to the soft tissues and making it unable to completely repair itself, and instead being replaced by fibrous tissue.

[0003] Danxiong scar coating is made of 12 Chinese medicinal herbs including salvia miltiorrhiza, angelica sinensis, chuanxiong, peach kernel, safflower, trillium, gallnut, sophora flavescens, frankincense (processed), myrrh (processed), borneol, and licorice, plus auxiliary materials. It can promote blood circulation, remove blood stasis, soften hard masses and relieve itching, and is used to reduce and assist scar hyperplasia.

[0004] The research on active ingredients of traditional Chinese medicine is one of the hot topics in drug development. How to screen the active ingredients of the twelve herbs in Danxiong scar coating and maximize their clinical value is the current challenge in the research and development of new drugs for Danxiong scar coating.

[0005] Based on previous research, the present invention develops a pharmaceutical composition for preventing and treating scar hyperplasia with clear ingredients and better effects through in-depth research on scar coating of Rhizoma Danxiong. Summary of the invention

[0006] Terms and Claims of the Present Invention:

[0007] 1. The articles "a", "an" and "the" include plural objects unless expressly limited to one or more objects in other ways.

[0008] 2. Numerical range: Unless otherwise expressly indicated, all ranges or ratios disclosed herein will be understood to include any and all sub-ranges or sub-ratios contained therein. For example, a range or ratio of 1 to 30 stated should be considered to be included between a minimum of 1 and a maximum of 30, and any sub-range or sub-ratio, integer, decimal, or sub-range or sub-ratio consisting of integers or decimals including the endpoints.

[0009] In view of the fact that the prior art has not yet found a method for screening the active ingredients of the Danxiong scar coating and developing a pharmaceutical composition for preventing and treating scar hyperplasia with clearer ingredients and better therapeutic effects, the purpose of the present invention is to provide a pharmaceutical composition for preventing and treating scar hyperplasia and its application. The pharmaceutical composition of the present invention has clear ingredients and better therapeutic effects than the Danxiong scar coating.

[0010] In order to achieve the above object, the present invention adopts the following technical solutions:

[0011] The invention provides a pharmaceutical composition for preventing and treating scar hyperplasia, comprising the following ingredients: danshensu, tanshinone ⅡA, salvianolic acid A, ligustilide, ferulic acid, ligustrin, ligustrazine, ligustrin A, amygdalin, β-sitosterol acetate, kaempferol, baicalin, safflower glycoside, p-hydroxybenzaldehyde, β-sitosterol, gallic acid, epicatechin gallate, granadine, matrine, matrine A, α-boswellic acid, β-boswellic acid, atractylodes lactone III, dehydrocostus lactone, borneol, glycyrrhizic acid and liquiritin.

[0012] Furthermore, the pharmaceutical composition comprises the following ingredients by weight: 20-50 parts of danshensu, 25-40 parts of tanshinone ⅡA, 20-45 parts of salvianolic acid A, 12-29 parts of ligustilide, 1-10 parts of ferulic acid, 20-40 parts of ligustrin, 15-40 parts of ligustrazine, 10-30 parts of ligustrin A, 5-25 parts of amygdalin, 5-20 parts of β-sitosterol acetate, 3-20 parts of kaempferol, 2-15 parts of scutellaria baicalensis, 3-25 parts of erythrocyte sedimentation rate, 1-2 parts of calendula officinalis ... Anthoglycosides, 5-25 parts of p-hydroxybenzaldehyde, 3-15 parts of β-sitosterol, 20-55 parts of gallic acid, 10-30 parts of epicatechin gallate, 15-30 parts of punica granatum, 5-25 parts of matrine, 5-30 parts of matrine A, 0.5-10 parts of α-boswellic acid, 1-15 parts of β-boswellic acid, 0.5-10 parts of atractylodes lactone III, 0.1-8 parts of dehydrocostus lactone, 0.1-3 parts of borneol, 1-8 parts of glycyrrhizic acid, and 0.5-10 parts of liquiritin.

[0013] Furthermore, the pharmaceutical composition comprises the following ingredients by weight: 25-45 parts of danshensu, 30-40 parts of tanshinone ⅡA, 25-40 parts of salvianolic acid A, 15-25 parts of ligustilide, 2-8 parts of ferulic acid, 23-37 parts of ligustrin, 17-38 parts of ligustrazine, 12-28 parts of ligustrin A, 7-23 parts of amygdalin, 7-18 parts of β-sitosterol acetate, 4-18 parts of kaempferol, 3-13 parts of scutellaria baicalensis, 5-2 2 parts of safflower glycosides, 7-23 parts of p-hydroxybenzaldehyde, 4-13 parts of β-sitosterol, 25-50 parts of gallic acid, 13-25 parts of epicatechin gallate, 18-27 parts of punica granatum, 7-20 parts of matrine, 7-25 parts of matrine A, 1-8 parts of α-boswellic acid, 3-12 parts of β-boswellic acid, 1-8 parts of atractylodes lactone III, 0.5-7 parts of dehydrocostus lactone, 0.3-2.5 parts of borneol, 2-7 parts of glycyrrhizic acid, and 1-9 parts of liquiritin.

[0014] Furthermore, the pharmaceutical composition comprises the following ingredients by weight: 30-40 parts of danshensu, 30-38 parts of tanshinone ⅡA, 25-35 parts of salvianolic acid A, 15-20 parts of ligustilide, 3-6 parts of ferulic acid, 25-35 parts of ligustrin, 20-35 parts of ligustrazine, 15-25 parts of ligustrin A, 10-20 parts of amygdalin, 9-16 parts of β-sitosterol acetate, 5-15 parts of kaempferol, 5-11 parts of scutellaria baicalensis, 7 -20 parts of safflower glycosides, 8-20 parts of p-hydroxybenzaldehyde, 5-10 parts of β-sitosterol, 30-45 parts of gallic acid, 15-20 parts of epicatechin gallate, 20-26 parts of punica granatum, 8-18 parts of matrine, 8-20 parts of matrine A, 2-7 parts of α-boswellic acid, 5-10 parts of β-boswellic acid, 2-7 parts of atractylodes lactone III, 0.8-6 parts of dehydrocostus lactone, 0.5-2 parts of borneol, 3-6 parts of glycyrrhizic acid, and 2-8 parts of liquiritin.

[0015] Furthermore, the pharmaceutical composition comprises the following ingredients in parts by weight: 35 parts of danshensu, 35 parts of tanshinone ⅡA, 30 parts of salvianolic acid A, 18 parts of ligustilide, 4 parts of ferulic acid, 28 parts of ligustrin, 30 parts of ligustrazine, 20 parts of ligustrin A, 15 parts of amygdalin, 12 parts of β-sitosterol acetate, 10 parts of kaempferol, 8 parts of baicalin, 12 parts of safflower glycosides, 14 parts of p-hydroxybenzaldehyde, 7 parts of β-sitosterol, 38 parts of gallic acid, 17 parts of epicatechin gallate, 22 parts of granadine, 13 parts of matrine, 14 parts of matrine A, 5 parts of α-boswellic acid, 7 parts of β-boswellic acid, 5 parts of atractylodes lactone III, 3 parts of dehydrocostus lactone, 1 part of borneol, 4 parts of glycyrrhizic acid, and 5 parts of liquiritin.

[0016] The present invention also provides a method for preparing the pharmaceutical composition, comprising the following steps:

[0017] Danshensu, tanshinone ⅡA, salvianolic acid A, ligustilide, ferulic acid, ligustrin, ligustrazine, ligustrin A, amygdalin, β-sitosterol acetate, kaempferol, scutellaria baicalensis glycosides, safflower glycosides, p-hydroxybenzaldehyde, β-sitosterol, gallic acid, epicatechin gallate, punica granatum, matrine, matrine A, α-boswellic acid, β-boswellic acid, atractylodes lactone Ⅲ, dehydrocostus lactone, borneol, glycyrrhizic acid and liquiritin are combined and mixed according to the formula amount to obtain the pharmaceutical composition.

[0018] The present invention also provides application of the pharmaceutical composition in preparing a drug for preventing and treating scar hyperplasia.

[0019] The present invention also provides a medicine for preventing and treating scar hyperplasia, comprising the medicine composition.

[0020] Furthermore, the medicine also includes medically acceptable excipients.

[0021] Furthermore, the dosage form of the medicine is ointment or spray.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] On the basis of the original Danxiong scar coating, the present invention screens the active ingredients of the formula to obtain the pharmaceutical composition comprising danshensu, tanshinone ⅡA, salvianolic acid A, ligustilide, ferulic acid, ligustrin, ligustrazine, ligustrin lactone A, amygdalin, β-sitosterol acetate, kaempferol, baicalin, safflower glycoside, p-hydroxybenzaldehyde, β-sitosterol, gallic acid, epicatechin gallate, punica granatum, matrine, matrine A, α-boswellic acid, β-boswellic acid, atractylodes lactone III, dehydrocostus lactone, borneol, glycyrrhizic acid and liquiritin. The formula has clear ingredients and high bioavailability. Compared with the original Danxiong scar coating, the pharmaceutical composition has more definite therapeutic effect, effectively and controllably produces quality, and has more advantages in preventing and treating scar hyperplasia. DETAILED DESCRIPTION

[0024] The following description of the embodiments is only used to help understand the method of the present invention and its core idea. It should be noted that for those of ordinary skill in the art, without departing from the principles of the present invention, several improvements and modifications may be made to the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention. The following description of the disclosed embodiments enables professionals and technicians in this field to implement or use the present invention. The various modifications to these embodiments will be apparent to professionals and technicians in this field, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but may be applied to a wider range consistent with the principles and novel features disclosed herein.

[0025] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0026] The present invention does not limit the sources of the raw materials used. Unless otherwise specified, the raw materials used in the present invention are all common commercial products in the technical field. The specific raw material information is shown in Table 1.

[0027] Table 1

[0028]

[0029]

[0030] Example 1

[0031] The pharmaceutical composition is composed of the following ingredients by weight: 35 parts of danshensu, 35 parts of tanshinone ⅡA, 30 parts of salvianolic acid A, 18 parts of ligustilide, 4 parts of ferulic acid, 28 parts of ligustrin, 30 parts of ligustrazine, 20 parts of ligustrin A, 15 parts of amygdalin, 12 parts of β-sitosterol acetate, 10 parts of kaempferol, 8 parts of baicalin, 12 parts of safflower glycosides, 14 parts of p-hydroxybenzaldehyde, 7 parts of β-sitosterol, 38 parts of gallic acid, 17 parts of epicatechin gallate, 22 parts of granadine, 13 parts of matrine, 14 parts of matrine A, 5 parts of α-boswellic acid, 7 parts of β-boswellic acid, 5 parts of atractylodes lactone III, 3 parts of dehydrocostus lactone, 1 part of borneol, 4 parts of glycyrrhizic acid, and 5 parts of liquiritin.

[0032] The preparation method of the above-mentioned pharmaceutical composition is: evenly mix the above-mentioned weight portions of danshensu, tanshinone ⅡA, salvianolic acid A, ligustilide, ferulic acid, ligustrin, ligustrazine, ligustrin A, amygdalin, β-sitosterol acetate, kaempferol, scutellaria baicalensis glycosides, safflower glycosides, p-hydroxybenzaldehyde, β-sitosterol, gallic acid, epicatechin gallate, punica granatum, matrine, matrine A, α-boswellic acid, β-boswellic acid, atractylodes lactone III, dehydrocostus lactone, borneol, glycyrrhizic acid, and liquiritin to obtain the composition.

[0033] Example 2

[0034] The pharmaceutical composition is composed of the following ingredients by weight: 20 parts of danshensu, 25 parts of tanshinone ⅡA, 20 parts of salvianolic acid A, 12 parts of ligustilide, 1 part of ferulic acid, 20 parts of ligustrin, 15 parts of ligustrazine, 10 parts of ligustrin A, 5 parts of amygdalin, 5 parts of β-sitosterol acetate, 3 parts of kaempferol, 2 parts of baicalin, 3 parts of safflower glycosides, 5 parts of p-hydroxybenzaldehyde, 3 parts of β-sitosterol, 20 parts of gallic acid, 10 parts of epicatechin gallate, 15 parts of granadine, 5 parts of matrine, 5 parts of matrine A, 0.5 parts of α-boswellic acid, 1 part of β-boswellic acid, 0.5 parts of atractylodes lactone III, 0.1 parts of dehydrocostus lactone, 0.1 parts of borneol, 1 part of glycyrrhizic acid, and 0.5 parts of liquiritin.

[0035] The preparation method is the same as Example 1.

[0036] Example 3

[0037] The pharmaceutical composition is composed of the following ingredients by weight: 50 parts of danshensu, 40 parts of tanshinone ⅡA, 45 parts of salvianolic acid A, 29 parts of ligustilide, 10 parts of ferulic acid, 40 parts of ligustrin, 40 parts of ligustrazine, 30 parts of ligustrin A, 25 parts of amygdalin, 20 parts of β-sitosterol acetate, 20 parts of kaempferol, 15 parts of baicalin, 25 parts of safflower glycosides, 25 parts of p-hydroxybenzaldehyde, 15 parts of β-sitosterol, 55 parts of gallic acid, 30 parts of epicatechin gallate, 30 parts of granadine, 25 parts of matrine, 30 parts of matrine A, 10 parts of α-boswellic acid, 15 parts of β-boswellic acid, 10 parts of atractylodes lactone III, 8 parts of dehydrocostus lactone, 3 parts of borneol, 8 parts of glycyrrhizic acid, and 10 parts of liquiritin.

[0038] The preparation method is the same as Example 1.

[0039] Example 4

[0040] The pharmaceutical composition is composed of the following ingredients by weight: 40 parts of danshensu, 30 parts of tanshinone ⅡA, 28 parts of salvianolic acid A, 23 parts of ligustilide, 7 parts of ferulic acid, 25 parts of ligustrin, 25 parts of ligustrazine, 15 parts of ligustrin A, 10 parts of amygdalin, 15 parts of β-sitosterol acetate, 15 parts of kaempferol, 12 parts of scutellaria baicalensis glycosides, 20 parts of safflower glycosides, 19 parts of p-hydroxybenzaldehyde, 10 parts of β-sitosterol, 30 parts of gallic acid, 25 parts of epicatechin gallate, 18 parts of granadine, 20 parts of matrine, 20 parts of matrine A, 2 parts of α-boswellic acid, 5 parts of β-boswellic acid, 3 parts of atractylodes lactone III, 6 parts of dehydrocostus lactone, 0.8 parts of borneol, 6 parts of glycyrrhizic acid, and 2 parts of liquiritin.

[0041] The preparation method is the same as Example 1.

[0042] Comparative Example 1

[0043] The difference between this comparative example and Example 1 is that the weight proportions of tanshinone ⅡA, ligustilide, ligustilide A, epicatechin gallate, matrine and liquiritin are different.

[0044] Specifically, the pharmaceutical composition is composed of the following ingredients by weight: 35 parts of danshensu, 20 parts of tanshinone ⅡA, 30 parts of salvianolic acid A, 35 parts of ligustilide, 4 parts of ferulic acid, 28 parts of ligustrin, 30 parts of ligustrazine, 5 parts of ligustrin A, 15 parts of amygdalin, 12 parts of β-sitosterol acetate, 10 parts of kaempferol, 8 parts of baicalin, 12 parts of safflower glycosides, 14 parts of p-hydroxybenzaldehyde, 7 parts of β-sitosterol, 38 parts of gallic acid, 35 parts of epicatechin gallate, 22 parts of granadine, 2 parts of matrine, 14 parts of matrine A, 5 parts of α-boswellic acid, 7 parts of β-boswellic acid, 5 parts of atractylodes lactone III, 3 parts of dehydrocostus lactone, 1 part of borneol, 4 parts of glycyrrhizic acid, and 11 parts of liquiritin.

[0045] The preparation method is the same as Example 1.

[0046] Comparative Example 2

[0047] The difference between this comparative example and Example 1 is that the weight proportions of tanshinone ⅡA, ligustilide, ligustilide A, epicatechin gallate, matrine and liquiritin are different.

[0048] Specifically, the pharmaceutical composition is composed of the following ingredients by weight: 35 parts of danshensu, 43 parts of tanshinone ⅡA, 30 parts of salvianolic acid A, 2 parts of ligustilide, 4 parts of ferulic acid, 28 parts of ligustrin, 30 parts of ligustrazine, 33 parts of ligustrin A, 15 parts of amygdalin, 12 parts of β-sitosterol acetate, 10 parts of kaempferol, 8 parts of baicalin, 12 parts of safflower glycosides, 14 parts of p-hydroxybenzaldehyde, 7 parts of β-sitosterol, 38 parts of gallic acid, 3 parts of epicatechin gallate, 22 parts of granadine, 26.9 parts of matrine, 14 parts of matrine A, 5 parts of α-boswellic acid, 7 parts of β-boswellic acid, 5 parts of atractylodes lactone III, 3 parts of dehydrocostus lactone, 1 part of borneol, 4 parts of glycyrrhizic acid, and 0.1 part of liquiritin.

[0049] The preparation method is the same as Example 1.

[0050] Comparative Example 3

[0051] The difference between this comparative example and Example 1 is that 3-n-butenylphenyl peptide in Angelica sinensis is used instead of ligustilide; formononetin in Sophora flavescens is used instead of matrine; epigallocatechin gallate in Galla chinensis is used instead of epicatechin gallate; and apigenin liquiritin in Licorice is used instead of liquiritin.

[0052] The preparation method is the same as Example 1.

[0053] Efficacy evaluation

[0054] 1. Experimental Animals

[0055] A total of 90 healthy adult New Zealand white rabbits of both sexes, weighing 1.5-2.0 kg, were used and acclimated for 1 week.

[0056] 2. Experimental drugs

[0057] (1) The pharmaceutical compositions of Examples 1-4 and Comparative Examples 1-3 were dissolved in physiological saline to a concentration of 300 mg / mL before use and applied externally.

[0058] (2) Danxiong scar coating, from Weihai Rensheng Pharmaceutical Company, approval number: National Medicine Standard Z20153068.

[0059] 3. Dosage Grouping

[0060] New Zealand white rabbits were randomly divided into 9 groups, with 10 rabbits in each group: a blank control group, a positive control group, a group treated with the drugs of Examples 1-4, and a group treated with the drugs of Comparative Examples 1-3.

[0061] 4. Test methods

[0062] (1) Model building

[0063] Rabbits were injected with 2% lidocaine for local anesthesia. Under strict aseptic operation techniques, the hair on the buttocks and left and right ribs of each rabbit was cut and removed with a depilatory agent. The position and area were marked, and a "well"-shaped wound was cut with a scalpel at the marked position. The area was 3×2cm and the depth was to break the dermis until bleeding. Medical ethanol was injected into a cotton ball and placed in the "well"-shaped wound and ignited for 1.5 minutes. The scab on the wound was removed on the 7th day after the operation. The wound was epithelialized on the 21st day. The scab fell off by itself to form an early hyperplastic scar animal model.

[0064] (2) Experimental group treatment

[0065] Administration group: After the wound surface was epithelialized, the Example 1-4 administration group and the Comparative Example 1-3 administration group were respectively given the pharmaceutical composition prepared in Example 1-4 and Comparative Example 13 for smear treatment, with a dose of 10 mg / cm 2 The positive control group was given Danxiong scar coating at a dose of 20 mg / cm 2 ; Blank control group: given the same dose of normal saline for smear treatment. The medication was continued for 21 days, and the wound scar condition was observed every day.

[0066] (3) Detection method

[0067] Scar thickness: The same person measured the thickness of scars formed on the wound surfaces of each group using a color ultrasound diagnostic apparatus under the same conditions.

[0068] Scar hardness: Use a scar hardness tester to measure scar hardness. Place the hardness tester vertically on the scar and skin to be tested. Use the weight of the hardness tester to act on the test site. Different measurement results will be displayed on the instrument according to the different hardness of different scars and skin. Convert the reading into hardness value in N / mm 2 Each rabbit was measured three times in parallel, and the average value was calculated.

[0069] The test results of scar thickness and scar hardness of rabbits are shown in Tables 2 and 3.

[0070] Table 2

[0071]

[0072] Note: In the same column, different letters in the superscript of data indicate significant differences among the groups, P < 0.05, and the same letters indicate no significant differences among the groups, P > 0.05.

[0073] Table 3

[0074]

[0075] Note: In the same column, different letters in the superscript of data indicate significant differences among the groups, P < 0.05, and the same letters indicate no significant differences among the groups, P > 0.05.

[0076] Before treatment, the wound healing of the rabbits had the characteristics of hyperplastic scars. After 3 weeks of treatment in the drug administration group, the scar tissue began to soften. As shown in Tables 2 and 3, compared with the blank control group, the scar hardness and scar thickness of the rabbits in the positive control group and Example 1-4 groups were significantly reduced (P < 0.05), indicating that the positive drug and the pharmaceutical composition provided by Example 1-4 groups have the effect of treating scar hyperplasia.

[0077] Compared with the positive control group, the scar hardness and scar thickness of the rabbits in Examples 1-4 groups were significantly reduced (P < 0.05), indicating that compared with the original research, the pharmaceutical composition obtained by screening the active ingredients of the formula in the present invention has a better effect in treating scar hyperplasia.

[0078] Comparison of comparative examples 1-3 groups shows that compared with the blank control group, the scar hardness and scar thickness of the rabbits in comparative examples 1-3 groups had no significant changes (P>0.05), indicating that the pharmaceutical composition provided by comparative examples 1-3 groups has no effect on treating scar hyperplasia.

[0079] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A pharmaceutical composition for preventing and treating scar hyperplasia, characterized in that: The invention is composed of the following ingredients by weight: 20-50 parts of danshensu, 25-40 parts of tanshinone ⅡA, 20-45 parts of salvianolic acid A, 12-29 parts of ligustilide, 1-10 parts of ferulic acid, 20-40 parts of ligustrin, 15-40 parts of ligustrazine, 10-30 parts of ligustrin A, 5-25 parts of amygdalin, 5-20 parts of β-sitosterol acetate, 3-20 parts of kaempferol, 2-15 parts of baicalin, 3-25 parts of safflower glycosides, 5-2 5 parts of p-hydroxybenzaldehyde, 3-15 parts of β-sitosterol, 20-55 parts of gallic acid, 10-30 parts of epicatechin gallate, 15-30 parts of punica granatum, 5-25 parts of matrine, 5-30 parts of matrine A, 0.5-10 parts of α-boswellic acid, 1-15 parts of β-boswellic acid, 0.5-10 parts of atractylodes lactone III, 0.1-8 parts of dehydrocostus lactone, 0.1-3 parts of borneol, 1-8 parts of glycyrrhizic acid, and 0.5-10 parts of liquiritin.

2. The pharmaceutical composition according to claim 1, characterized in that The invention is composed of the following ingredients by weight: 25-45 parts of danshensu, 30-40 parts of tanshinone ⅡA, 25-40 parts of salvianolic acid A, 15-25 parts of ligustilide, 2-8 parts of ferulic acid, 23-37 parts of ligustrin, 17-38 parts of ligustrazine, 12-28 parts of ligustrin A, 7-23 parts of amygdalin, 7-18 parts of β-sitosterol acetate, 4-18 parts of kaempferol, 3-13 parts of baicalin, 5-22 parts of safflower glycosides, 7-23 parts of p-hydroxybenzaldehyde, 4-13 parts of β-sitosterol, 25-50 parts of gallic acid, 13-25 parts of epicatechin gallate, 18-27 parts of punica granatum, 7-20 parts of matrine, 7-25 parts of matrine A, 1-8 parts of α-boswellic acid, 3-12 parts of β-boswellic acid, 1-8 parts of atractylodes lactone III, 0.5-7 parts of dehydrocostus lactone, 0.3-2.5 parts of borneol, 2-7 parts of glycyrrhizic acid, and 1-9 parts of liquiritin.

3. The pharmaceutical composition according to claim 2, characterized in that The invention is composed of the following ingredients by weight: 30-40 parts of danshensu, 30-38 parts of tanshinone ⅡA, 25-35 parts of salvianolic acid A, 15-20 parts of ligustilide, 3-6 parts of ferulic acid, 25-35 parts of ligustrin, 20-35 parts of ligustrazine, 15-25 parts of ligustrin A, 10-20 parts of amygdalin, 9-16 parts of β-sitosterol acetate, 5-15 parts of kaempferol, 5-11 parts of baicalin, and 7-20 parts of safflower glycosides. , 8-20 parts of p-hydroxybenzaldehyde, 5-10 parts of β-sitosterol, 30-45 parts of gallic acid, 15-20 parts of epicatechin gallate, 20-26 parts of punica granatum, 8-18 parts of matrine, 8-20 parts of matrine A, 2-7 parts of α-boswellic acid, 5-10 parts of β-boswellic acid, 2-7 parts of atractylodes lactone III, 0.8-6 parts of dehydrocostus lactone, 0.5-2 parts of borneol, 3-6 parts of glycyrrhizic acid, and 2-8 parts of liquiritin.

4. The pharmaceutical composition according to claim 3, characterized in that The invention is composed of the following ingredients by weight: 35 parts of danshensu, 35 parts of tanshinone ⅡA, 30 parts of tanshinone acid A, 18 parts of ligustilide, 4 parts of ferulic acid, 28 parts of ligustrin, 30 parts of ligustrazine, 20 parts of ligustrin lactone A, 15 parts of amygdalin, 12 parts of β-sitosterol acetate, 10 parts of kaempferol, 8 parts of baicalin, 12 parts of safflower glycosides, 14 parts of p-hydroxybenzaldehyde, 7 parts of β-sitosterol, 38 parts of gallic acid, 17 parts of epicatechin gallate, 22 parts of punica granatum, 13 parts of matrine, 14 parts of matrine A, 5 parts of α-boswellic acid, 7 parts of β-boswellic acid, 5 parts of atractylodes lactone III, 3 parts of dehydrocostus lactone, 1 part of borneol, 4 parts of glycyrrhizic acid and 5 parts of glycyrrhizin.

5. The method for preparing the pharmaceutical composition according to any one of claims 1 to 4, characterized in that: The following steps are involved: Danshensu, tanshinone ⅡA, salvianolic acid A, ligustilide, ferulic acid, ligustrin, ligustrazine, ligustrin A, amygdalin, β-sitosterol acetate, kaempferol, scutellaria baicalensis glycosides, safflower glycosides, p-hydroxybenzaldehyde, β-sitosterol, gallic acid, epicatechin gallate, punica granatum, matrine, matrine A, α-boswellic acid, β-boswellic acid, atractylodes lactone Ⅲ, dehydrocostus lactone, borneol, glycyrrhizic acid and liquiritin are combined and mixed according to the formula amount to obtain the pharmaceutical composition.

6. Use of the pharmaceutical composition according to any one of claims 1 to 4 or the pharmaceutical composition prepared by the preparation method according to claim 5 in preparing a drug for preventing and treating scar hyperplasia.

7. A drug for preventing and treating scar hyperplasia, characterized in that: A pharmaceutical composition comprising any one of claims 1 to 4.

8. The drug according to claim 7, characterized in that Medically accepted excipients are also included.

9. The drug according to claim 8, characterized in that The dosage form of the medicine is ointment or spray.

Images